- Home
- CDXS vs RIGL Comparison
CDXS vs RIGL Comparison
Compare CDXS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- RIGL
- Stock Information
- Founded
- CDXS 2002
- RIGL 1996
- Country
- CDXS United States
- RIGL United States
- Employees
- CDXS N/A
- RIGL N/A
- Industry
- CDXS Major Chemicals
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- RIGL Health Care
- Exchange
- CDXS Nasdaq
- RIGL Nasdaq
- Market Cap
- CDXS 406.9M
- RIGL 486.4M
- IPO Year
- CDXS 2010
- RIGL 2000
- Fundamental
- Price
- CDXS $5.13
- RIGL $21.81
- Analyst Decision
- CDXS Buy
- RIGL Buy
- Analyst Count
- CDXS 2
- RIGL 5
- Target Price
- CDXS $11.00
- RIGL $34.80
- AVG Volume (30 Days)
- CDXS 739.7K
- RIGL 347.9K
- Earning Date
- CDXS 02-26-2025
- RIGL 03-04-2025
- Dividend Yield
- CDXS N/A
- RIGL N/A
- EPS Growth
- CDXS N/A
- RIGL N/A
- EPS
- CDXS N/A
- RIGL 0.22
- Revenue
- CDXS $64,446,000.00
- RIGL $157,374,000.00
- Revenue This Year
- CDXS N/A
- RIGL $51.34
- Revenue Next Year
- CDXS $2.02
- RIGL $15.75
- P/E Ratio
- CDXS N/A
- RIGL $98.50
- Revenue Growth
- CDXS N/A
- RIGL 21.65
- 52 Week Low
- CDXS $2.53
- RIGL $7.48
- 52 Week High
- CDXS $6.08
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- CDXS 58.39
- RIGL 64.53
- Support Level
- CDXS $4.24
- RIGL $17.28
- Resistance Level
- CDXS $5.51
- RIGL $18.25
- Average True Range (ATR)
- CDXS 0.32
- RIGL 1.37
- MACD
- CDXS 0.00
- RIGL 0.65
- Stochastic Oscillator
- CDXS 82.68
- RIGL 99.68
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.